Ensysce Biosciences Inc (LACQ)


Stock Price Forecast

June 30, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ensysce Biosciences Inc chart...

About the Company

LACQ is a blank check company formed for the purpose of effecting a merger or other business combination with a target company. Leisure is led by Lorne Weiland Daniel Silversand completed its Initial Public Offering in December 2017.

Employees

7915

Exchange

OTC PINK CURRENT

Website

leisureacq.com

$4M

Total Revenue

8K

Employees

$87M

Market Capitalization

-85.24

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LACQ News

Q4 2023 Ensysce Biosciences Inc Earnings Call

6d ago, source:

Ram Selvaraju; Analyst; H.C. Wainwright & Company Inc ...

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

1mon ago, source: Morningstar

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription ...

Ensysce Biosciences Inc Ordinary Shares

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

14d ago, source: Stockhouse

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / ...

Ensysce Biosciences Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

1mon ago, source: Nasdaq

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve ...

Ensysce Biosciences, Inc.: Ensysce Biosciences Receives Positive Nasdaq Listing Determination

1mon ago, source: Finanznachrichten

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug ...

Ensysce Biosciences Inc (ENSC)

1mon ago, source: Investing

SAN DIEGO, CA - Ensysce Biosciences, Inc. (NASDAQ:ENSC), a biotech firm focused on enhancing prescription drug safety, has announced agreements for the immediate exercise of... SAN DIEGO, CA ...

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

1mon ago, source: Stockhouse

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024/Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription ...

Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

13d ago, source:

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / E ...

ENSC Ensysce Biosciences, Inc.

22d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...